Compare iShares MSCI Indonesia ETF (EIDO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Stryker Corporation — how do they compare? iShares MSCI Indonesia ETF trades at $12.68, while Stryker Corporation trades at $345.18 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while iShares MSCI Indonesia ETF pays none, and Stryker Corporation is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | SYK | |
|---|---|---|
52-Week High | $19.22 | $394.34 |
52-Week Low | $10.80 | $282.58 |
Market Cap | — | $133.54B |
Sector | — | Technology |
Enterprise Value | — | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO, the iShares MSCI Indonesia ETF, trades at $12.675, down 0.59% today, with a bearish technical signal from moving averages. The fund's valuation appears low, but financial data for the current period is unavailable. Recent news highlights Indonesia's economic initiatives and central bank policy shifts, while technical indicators show neutral oscillators and defined support at $12.
The outlook is mixed, with potential from Indonesia's GDP growth initiatives but weighed by foreign capital outflows and a strong financials weighting. Risks include currency volatility and dependence on commodity markets. Analyst sentiment is neutral due to weak price action despite attractive valuations.
Stryker (SYK) trades at $341.17, down 1.34% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 results with a 9% organic sales growth and an EPS beat, recovering from a Q1 cyber incident. Profitability remains robust with a net income margin of 14.43% and a dividend yield supported by recent increases.
The stock offers upside potential driven by earnings momentum and product innovation like Mako RPS, but risks include competitive pressures and past cybersecurity disruptions. Analyst sentiment is strongly bullish with 74% buy ratings, though valuation multiples like a P/E of 36.08 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
